Several published trials have shown that the occurrence of irAEs might be associated with substantially improved ORR, PFS, and OS in patients with NSCLC who were treated with PD-1/PD-L1 inhibitor monotherapy [107–109]. Here, PDCD1 is linked to non-small cell lung carcinoma.